|Classification and external resources|
Post-polio syndrome (PPS, or post-poliomyelitis syndrome or post-polio sequelae) is a condition that affects approximately 25–50% of people who have previously contracted poliomyelitis—a viral infection of the nervous system—after the initial infection. Typically the symptoms appear 15–30 years after recovery from the original paralytic attack, at an age of 35 to 60. Symptoms include acute or increased muscular weakness, pain in the muscles, and fatigue. The same symptoms may also occur years after a nonparalytic polio (NPP) infection.
The precise mechanism that causes PPS is unknown. It shares many features with chronic fatigue syndrome, but unlike that disorder, it tends to be progressive, and can cause loss of muscle strength. Treatment is primarily limited to adequate rest, conservation of available energy, and supportive measures, such as leg braces and energy-saving devices such as powered wheelchairs, analgesia (pain relief) and sleep aids.
Signs and symptomsEdit
After a period of prolonged stability individuals who had been infected and recovered from polio begin to experience new signs and symptoms, characterised by muscular atrophy (decreased muscle mass), weakness, pain and fatigue in limbs that were originally affected or in limbs that didn't seem to have been affected at the time of the initial polio illness. PPS is a very slowly progressing condition marked by periods of stability followed by new declines in the ability to carry out usual daily activities. Most patients become aware of their decreased capacity to carry out daily routines due to significant changes in mobility, decreasing upper limb function and lung capability. Fatigue is often the most disabling symptom; even slight exertion often produces disabling fatigue and can also intensify other symptoms. Problems breathing or swallowing, sleep-related breathing disorders, such as sleep apnea and decreased tolerance for cold temperatures are other notable symptoms.
Increased activity during intervening healthy years between the original infection and onset of PPS can amplify the symptoms. Thus, contracting poliomyelitis at a young age can result in particularly disabling PPS symptoms.
Numerous theories have been proposed to explain post-polio syndrome. Despite this, there are currently no absolutely defined causes of PPS. The most widely accepted theory of the mechanism behind the disorder is "neural fatigue". A motor unit is a nerve cell (or neuron) and the muscle fibers it activates. Poliovirus attacks specific neurons in the brainstem and the anterior horn cells of the spinal cord, generally resulting in the death of a substantial fraction of the motor neurons controlling skeletal muscles. In an effort to compensate for the loss of these neurons, surviving motor neurons sprout new nerve terminals to the orphaned muscle fibers. The result is some recovery of movement and the development of enlarged motor units.
The neural fatigue theory proposes that the enlargement of the motor neuron fibres places added metabolic stress on the nerve cell body to nourish the additional fibers. After years of use, this stress may be more than the neuron can handle, leading to the gradual deterioration of the sprouted fibers and, eventually, the neuron itself. This causes muscle weakness and paralysis. Restoration of nerve function may occur in some fibers a second time, but eventually nerve terminals malfunction and permanent weakness occurs. When these neurons no longer carry on sprouting, fatigue occurs due to the increasing metabolic demand of the nervous system. The normal aging process also may play a role. There is an ongoing denervation and reinnervation, but the reinnervation process has an upper limit where the reinnervation cannot compensate for the ongoing denervation, and loss of motor units takes place. However, what disturbs the denervation-reinnervation equilibrium and causes peripheral denervation is still unclear. With age, most people experience a decrease in the number of spinal motor neurons. Because polio survivors have already lost a considerable number of motor neurons, further age-related loss of neurons may contribute substantially to new muscle weakness. The overuse and underuse of muscles also may contribute to muscle weakness.
Another theory is that people who have recovered from polio lose remaining healthy neurons at a faster rate than normal. However, little evidence exists to support this idea. Finally, it has been proposed that the initial polio infection causes an autoimmune reaction, in which the body's immune system attacks normal cells as if they were foreign substances. Again, compared to neural fatigue, the evidence supporting this theory is quite limited.
Diagnosis of post-polio syndrome can be difficult, since the symptoms are hard to separate from complications due to the original poliomyelitis infection, and from the normal infirmities of aging. There is no laboratory test for post-polio syndrome, nor are there any other specific diagnostic criteria. Three important criteria are recognized, including: previous diagnosis of polio, long interval after recovery and the gradual onset of weakness.
In general, PPS is a diagnosis of exclusion whereby other possible causes of the symptoms are eliminated. Neurological examination aided by other laboratory studies can help to determine what component of a neuromuscular deficit occurred with polio and what components are new and to exclude all other possible diagnoses. Objective assessment of muscle strength in PPS patients may not be easy. Changes in muscle strength are determined in specific muscle groups using various muscle scales which quantify strength, such as the Medical Research Council (MRC) scale. Magnetic resonance imaging (MRI), neuroimaging, and electrophysiological studies, muscle biopsies, or spinal fluid analysis may also be useful in establishing a PPS diagnosis.
The treatment for post-polio syndrome is generally palliative and consists of rest, analgesia (pain relief) and utilisation of mechanisms to make life easier such as powered wheelchairs. There are no reversive therapies. Fatigue is usually the most disabling symptom; energy conservation can significantly reduce fatigue episodes. Such conservation can be achieved with lifestyle changes, reducing workload and daytime sleeping. Weight loss is also recommended if patients are obese. In some cases, the use of lower limb orthotics can reduce energy usage. Medications for fatigue, such as amantadine and pyridostigmine, have not been found to be effective in the management of PPS. Muscle strength and endurance training are more important in managing the symptoms of PPS than the ability to perform long aerobic activity. Management should focus on treatments such as hydrotherapy and developing other routines that encourage strength but do not affect fatigue levels. The recent trend is towards use of intravenous immunoglobulin (IVIG) which has yielded promising, albeit modest results, but as of 2010[update] there is insufficient evidence to recommend it as a treatment.
PPS increases the stress on the musculoskeletal system due to increasing muscular atrophy. A recent study showed that in a review of 539 PPS patients, 80% reported pain in muscles and joints and 87% only had fatigue. Joint instability can cause significant pain in individuals with PPS should be adequately treated with painkillers. Supervised activity programs, decreasing mechanical stress with braces and adaptive equipment is recommended.
Because PPS can fatigue facial muscles, as well as cause dysphagia (difficulty swallowing), dysarthria (difficulty speaking) or aphonia (inability to produce speech), persons with PPS may become malnourished due to difficulty eating. Compensatory routines can help relieve these symptoms such as eating smaller portions at a time and sitting down whilst eating. PPS with respiratory involvement requires special management such as breathing exercises, chest percussion with a stethoscope on regular occasions for observation of the disease and management of secretions. Failure to properly assess PPS with respiratory involvement can increase the risk of missing aspiration pneumonia (an infection of the lower respiratory tract) in an individual. Severe cases may require permanent ventilation or tracheostomy. Sleep apnoea may also occur. Other management strategies that may lead to improvement include smoking cessation, treatment of other respiratory diseases and vaccination against respiratory infections such as influenza.
In general, PPS is not life-threatening. The major exception are patients left with severe residual respiratory difficulties, who may experience new severe respiratory impairment. Studies have shown that, compared to control populations, PPS patients lack any elevation of antibodies against the poliovirus, and because no poliovirus is excreted in the feces, it is not considered a recurrence of the original polio. Further, there is no evidence that the poliovirus can cause a persistent infection in humans. PPS has been confused with amyotrophic lateral sclerosis (ALS), which progressively weakens muscles. PPS patients do not have an elevated risk of ALS.
There have been no sufficient longitudinal studies on the prognosis of post-polio syndrome; however, speculations have been made by several physicians based on experience. Fatigue and mobility usually return to normal over a long period of time. The prognosis also differs depending upon different causes and factors affecting the individual. An overall mortality rate of 25% exists due to possible respiratory paralysis of persons with post-polio syndrome; otherwise, post-polio syndrome is usually non-lethal.
Post-polio syndrome occurs in approximately 25–50% of people who survive a poliomyelitis infection. On average, it occurs 30–35 years afterwards; however, delays of between 8–71 years have been recorded. The disease occurs sooner in persons with more severe initial infection. Other factors that increase the risk of postpolio syndrome include increasing length of time since acute poliovirus infection, presence of permanent residual impairment after recovery from the acute illness, and being female.
Post-polio syndrome is documented to occur in cases of nonparalytic polio (NPP). One review states late-onset weakness and fatigue occurs in 14% to 42% of NPP patients.
- Jonas, Gerald (18 March 2008). "Arthur C. Clarke, Premier Science Fiction Writer, Dies at 90.". New York Times. Retrieved 19 March 2008.
- "Post-polio syndrome: Symptoms". MayoClinic.com. Retrieved 23 February 2009.
- "Post-Polio Syndrome Fact Sheet: National Institute of Neurological Disorders and Stroke (NINDS)". Retrieved 30 December 2008.
- Jubelt B, Agre JC (2000). "Characteristics and management of postpolio syndrome". JAMA 284 (4): 412–4. doi:10.1001/jama.284.4.412. PMID 10904484.
- Howard RS (June 2005). "Poliomyelitis and the postpolio syndrome". BMJ 330 (7503): 1314–8. doi:10.1136/bmj.330.7503.1314. PMC 558211. PMID 15933355. Retrieved 24 December 2008.
- Khan F (August 2004). "Rehabilitation for postpolio sequelae". Aust Fam Physician 33 (8): 621–4. PMID 15373379. Retrieved 24 December 2008.
- Dalakas, MC; Elder, G, Hallett, M, Ravits, J, Baker, M, Papadopoulos, N, Albrecht, P, Sever, J (10 April 1986). "A long-term follow-up study of patients with post-poliomyelitis neuromuscular symptoms.". The New England Journal of Medicine 314 (15): 959–63. doi:10.1056/NEJM198604103141505. PMID 3007983.
- "Post-polio syndrome: Causes". MayoClinic.com. Retrieved 23 February 2009.
- Stolwijk-Swüste JM, Beelen A, Lankhorst GJ, Nollet F (August 2005). "The course of functional status and muscle strength in patients with late-onset sequelae of poliomyelitis: a systematic review". Arch Phys Med Rehabil 86 (8): 1693–701. doi:10.1016/j.apmr.2004.12.022. PMID 16084828.
- "Post-polio syndrome: Tests and diagnosis". MayoClinic.com. Retrieved 23 February 2009.
- Silver JK, Gawne AC (2003). Postpolio Syndrome. Philadelphia: Hanley & Belfus. ISBN 1-56053-606-3.
- Horemans, HL; Nollet, F, Beelen, A, Drost, G, Stegeman, DF, Zwarts, MJ, Bussmann, JB, de Visser, M, Lankhorst, GJ (2003 Dec). "Pyridostigmine in postpolio syndrome: no decline in fatigue and limited functional improvement.". Journal of neurology, neurosurgery, and psychiatry 74 (12): 1655–61. PMC 1757426. PMID 14638885.
- Trojan, DA; Collet, JP, Shapiro, S, Jubelt, B, Miller, RG, Agre, JC, Munsat, TL, Hollander, D, Tandan, R, Granger, C, Robinson, A, Finch, L, Ducruet, T, Cashman, NR (12 October 1999). "A multicenter, randomized, double-blinded trial of pyridostigmine in postpolio syndrome.". Neurology 53 (6): 1225–33. PMID 10522877.
- Farbu E (2010). "Update on current and emerging treatment options for post-polio syndrome". Ther Clin Risk Manag 6: 307–13. doi:10.2147/TCRM.S4440. PMC 2909497. PMID 20668713.
- Koopman, FS.; Uegaki, K.; Gilhus, NE.; Beelen, A.; de Visser, M.; Nollet, F. (2011). "Treatment for postpolio syndrome.". Cochrane Database Syst Rev (2): CD007818. doi:10.1002/14651858.CD007818.pub2. PMID 21328301.
- Ehde DM, Jensen MP, Engel JM, Turner JA, Hoffman AJ, Cardenas DD (2003). "Chronic pain secondary to disability: a review". Clin J Pain 19 (1): 3–17. doi:10.1097/00002508-200301000-00002. PMID 12514452. Retrieved 24 December 2008.
- Silbergleit AK, Waring WP, Sullivan MJ, Maynard FM (March 1991). "Evaluation, treatment, and follow-up results of post polio patients with dysphagia". Otolaryngol Head Neck Surg 104 (3): 333–8. PMID 1902934.
- Lindsay, Kenneth W; Ian Bone, Robin Callander, J. van Gijn (1991). Neurology and Neurosurgery Illustrated. United States: Churchill Livingstone. pp. 489–490. ISBN 0-443-04345-0.
- Jubelt, B; J Drucket (1999). Poliomyelitis and the Post-Polio Syndrome in Motor Disorders. Philadelphia: Lippincott Williams and Wilkins. p. 381.
- Jubelt B, Cashman NR (1987). "Neurological manifestations of the post-polio syndrome". Crit Rev Neurobiol 3 (3): 199–220. PMID 3315237.
- Ramlow J, Alexander M, LaPorte R, Kaufmann C, Kuller L (October 1992). "Epidemiology of the post-polio syndrome". Am. J. Epidemiol. 136 (7): 769–86. doi:10.1093/aje/136.7.769. PMID 1442743. Retrieved 24 December 2008.
- Atkinson W, Hamborsky J, McIntyre L, Wolfe S (eds.) (2012). "11". Epidemiology and Prevention of Vaccine-Preventable Diseases (The Pink Book) (12th ed.). Washington DC: Public Health Foundation.
- Bruno RL (2000). "Paralytic vs. "nonparalytic" polio: distinction without a difference?". Am J Phys Med Rehabil 79 (1): 4–12. doi:10.1097/00002060-200001000-00003. PMID 10678596.
- Bruno, Richard L. (2002). The Polio Paradox. New York: Warner Books. ISBN 0-446-52907-9.
- Maynard, F.M., & Headley, J.H. (Eds.) (1999). Handbook on the Late Effects of Poliomyelitis for Physicians and Survivors. Saint Louis, MO: GINI (now Post-Polio Health International). Information on 90 post-polio topics; a compilation of the research and experience of over 40 experts.
- March of Dimes Birth Defects Foundation. (1999). Identifying Best Practices in Diagnosis & Care. Warm Springs, GA: March of Dimes International Conference on Post-Polio Syndrome
- Nollet F. "Perceived health and physical functioning in postpoliomyelitis syndrome". Vrije Universiteit Amsterdam, 2002.
- Nollet, F. "Post-polio syndrome". Orphanet Ecyclopaedia, 2003
- Silver, Julie K. (2001). Post-Polio Syndrome: A Guide for Polio Survivors and Their Families. New Haven: Yale University Press. (Dr. Silver is Medical Director, Spaulding-Framingham Outpatient Center; Assistant Professor, Department of Physical Medicine and Rehabilitation, Harvard Medical School.)
- National Institute of Neurological Disorders and Stroke-Post-polio
- Lincolnshire Post-Polio Library
- Post-Polio Health International
- Post-Polio Syndrome and Erectile Dysfunction